Abstract
Cocaine abuse and dependence constitute major health and social problems in the US and elsewhere. They are associated with a wide range of psychiatric and medical morbidity, including an increased risk of transmission of HIV.
The 2 major approaches to the treatment of cocaine abuse and dependence are psychosocial interventions and pharmacotherapy to reduce withdrawal and craving, and to ensure abstinence initiation and relapse prevention. These approaches are often combined to optimise outcome. Numerous medications have been tested in the treatment of cocaine dependence. To date, however, there is no conclusive evidence in support of any generally effective pharmacotherapy for cocaine craving, withdrawal or abstinence initiation. Therefore, the mainstay of treatment is the use of psychosocial interventions.
Similar content being viewed by others
References
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
Goldstein A. The wild addictions: cocaine and amphetamines. In: Addiction: from biology to drug policy. New York (NY): W.H. Freeman and Company, 1994: 155–67
Benowitz N. Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol 1993; 72: 3–12
Jones RT. The pharmacology of cocaine. In: Grabowski J, editor. Cocaine: pharmacology, effects, and treatment of abuse. NIDA Res Monogr 1984; 50: 34–53
Gold MS. The neurobiology of addictive disorders: the role of dopamine, endorphin and serotonin. In: Miller NS, editor. The principles and practice of addictions in psychiatry. Philadelphia: W.B. Saunders Company, 1997: 57–69
Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Arch Gen Psychiatry 1986; 43: 107–13
Lago JA, Kosten TR. Stimulant withdrawal. Addiction 1994; 89(11): 1477–81
Gawin FH. Cocaine addiction: psychology and neurophysiology. Science 1991; 251: 1580–6
Preliminary estimates from the 1995 National Household Survey on Drug Abuse (NHSDA). http://www.health.org/pubs/ 95hhs/ar18txt.htm
Preliminary estimates from the Drug Abuse Warning Network (DAWN): 1996 DAWN survey. http://www.health.org/pubs/ 96dawn/ar17.htm
Larrat EP, Ziegler S. Entangled epidemics: cocaine use and HIV disease. J Psychoactive Drugs 1993; 25(3): 207–21
Goldstein PJ, Oullet LJ, Fendrich M. From bags brides to skeezers: a historical perspective on sex-for-drugs behavior. J Psychoactive Drugs 1992; 24(4): 349–61
Haim DY, Lippmann ML, Goldberg SK, et al. The pulmonary complications of crack cocaine: a comprehensive review. Chest 1995; 107: 233–40
O’Connor PG, Chang G, Shi J. Medical complications of cocaine use. In: Kosten TR, Kleber HD, editors. Clinician’s guide to cocaine addiction: theory, research and treatment. New York/London: The Guilford Press, 1992: 241–72
Fox CH. Cocaine use in pregnancy. J Am Board Fam Pract 1994; 7: 225–8
Halikas JA, Crosby RD, Pearson VL, et al. Psychiatric comorbidity in treatment-seeking cocaine abusers. Am J Addict 1994; 3(1): 25–35
Ziedonis DM, Rayford BS, Bryant KJ, et al. Psychiatric comorbidity in whites and African-American cocaine addicts seeking substance abuse treatment. Hosp Community Psychiatry 1994; 45(1): 43–9
Kleinman PA, Miller AB, Millman RB, et al. Psychopathology among cocaine abusers entering treatment. J Nerv Ment Dis 1990; 178(7): 442–7
Des Jarlais DC. Harm reduction: a framework for incorporating science in drug policy. Am J Pub Health 1995; 85(1): 10–2
American Psychiatric Association. Practice guidelines for the treatment of patients with substance use disorders: alcohol, cocaine, opioids. Am J Psychiatry 1995; 152(11 Suppl.): 1–59
Budde D, Rounsaville B, Bryant K. Inpatient and outpatient cocaine abusers: clinical comparisons at intake and one-year follow-up. J Subst Abuse Treat 1992; 9(4): 337–42
Alterman AI, O’Brien CP, McLellan AT, et al. Effectiveness and costs of inpatient versus day hospital cocaine rehabilitation. J Nerv Ment Dis 1994; 182(3): 157–63
United States General Accounting Office. Cocaine treatment: early results from various approaches. Washington, DC: US Government Printing Office, 1996 Jun: 1–34
Schuckit MA. Drug and alcohol abuse: a clinical guide to diagnosis and treatment. 4th ed. New York (NY): Plenum, 1995: 328–30
Carroll KM, Rounsaville BJ, Keller DS. Relapse prevention strategies for the treatment of cocaine abuse. Am J Drug Alcohol Abuse 1991; 17(3): 249–65
Carroll KM, Rounsaville BJ, Gawin FH. A comparative trial of psychotherapies for ambulatory cocaine abusers: relapse prevention and interpersonal psychotherapy. Am J Drug Alcohol Abuse 1991; 17(3): 229–47
Carroll KM, Rounsaville BJ, Gordon LT, et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry 1994; 51: 177–87
Wallace BC. Treating crack cocaine dependence: the critical role of relapse prevention. J Psychoactive Drugs 1992; 24(2): 213–22
Higgins ST, Budney AJ. Treatment of cocaine dependence through the principles of behavior analysis and behavioral pharmacology. In: Onken LS, Blaine JD, Boren JJ, editors. Behavioral treatments for drug abuse and dependence. NIDA Res Monogr 1993: 139: 97–121
Higgins ST, Budney AJ, Bickel WK, et al. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry 1993; 150(5): 763–8
Higgins ST, Budney AJ, Bickel WK, et al. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 1994; 51: 568–76
Silverman K, Higgins ST, Brooner RK, et al. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry 1996; 53: 409–15
Rawson RA, Obert JL, McCann MJ, et al. Psychological approaches for the treatment of cocaine dependence: a neurobehavioral approach. J Addictive Dis 1991; 11(2): 97–119
Shoptaw S, Rawson RA, McCann MJ, et al. The matrix model of outpatient stimulant abuse treatment: evidence of efficacy. J Addict Dis 1994; 13(4): 129–41
Hoffman JA, Caudill BD, Koman JJ, et al. Psychosocial treatments for cocaine abuse: 12-month treatment outcomes. J Subst Abuse Treat 1996; 13(1): 3–11
Frawley PJ, Smith JW. Chemical aversion therapy in the treatment of cocaine dependence as part of a multimodal treatment program: treatment outcome. J Subst Abuse Treat 1990; 7: 21–9
Smith MO. Acupuncture treatment for crack: clinical survey of 1500 patients treated. Am J Acupuncture 1988; 16: 241–7
Margolin A, Avants SK, Chang C, et al. Acupuncture for the treatment of cocaine dependence in methadone-maintained patients. Am J Addict 1993; 2(3): 194–201
Avants SK, Margolin A, Chang P, et al. Acupuncture for the treatment of cocaine addiction: investigation of a needle puncture control. J Subst Abuse Treat 1995; 12(3): 195–205
Johnson DN, Vocci FJ. Medications development at the National Institute on Drug Abuse: cocaine. NIDA Res Monogr 1993; 135: 57–70
Landry DW. Immunotherapy for cocaine addiction. Sci Am 1997 Feb; 276(2): 42–5
Kosten TR, Morgan CM, Falcione J, et al. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry 1992; 49: 894–8
Handelsman L, Limpitlaw L, Williams D, et al. Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients. Drug Alcohol Depend 1995; 39(3): 173–80
Kampman K, Volpicelli JR, Alterman A, et al. Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. Drug Alcohol Depend 1996; 41(1): 25–33
Alterman AI, Droba M, Antelo RE, et al. Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend 1992; 31(1): 19–29
Margolin A, Kosten TR, Avants SK, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 1995; 40: 125–31
Giannini AJ, Baumgartel P, DiMarzio LR. Bromocriptine therapy in cocaine withdrawal. J Clin Pharmacol 1987; 27: 267–70
Preston KL, Sullivan JT, Strain EC, et al. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharmacol Exp Ther 1992; 292: 279–91
Moscovitz H, Brookoff D, Nelson L. A randomized trial of bromocriptine for cocaine users presenting to the emergency department. J Gen Intern Med 1993; 8: 1–4
Handelsman L, Rosenblum A, Palij M, et al. Bromocriptine for cocaine dependence: a controlled clinical trial. Am J Addict 1997; 6(1): 54–64
Oliveto AH, Kosten TR, Schottenfeld R, et al. Cocaine use in buprenorphine vs methadone-maintained patients. Am J Addict 1994; 3(1): 43–8
Hatsukami D, Keenan R, Halikas J, et al. Effects of carbamazepine on acute responses to smoked cocaine-base in human cocaine users. Psychopharmacology 1991; 104: 120–4
Cornish JW, Maany I, Fudala PJ, et al. Carbamazepine treatment for cocaine dependence [abstract]. 147th Annual Meeting of the American Psychiatric Association, 1994 May 21-6; Philadelphia
Gawin FH, Kleber H, Byck R, et al. Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry 1989; 46: 117–21
Levin FR, Lehman AF. Meta-analysis of desipramine as an adjunct in the treatment of cocaine addiction. J Clin Pharmacol 1991; 11(6): 374–8
Arndt IO, Dorozynsky L, Woody GE, et al. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch Gen Psychiatry 1992; 49(11): 888–93
Carroll KM, Rounsaville BJ, Gordon LT, et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry 1994; 51: 177–87
Hall SM, Tunis S, Triffleman E, et al. Continuity of care and desipramine in primary cocaine abusers. J Nerv Ment Dis 1994; 182(10): 570–5
Batki SL, Washburn AM, Delucchi K, et al. Acontrolled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend 1996; 41: 137–42
Grabowski J, Rhoades H, Elk R, et al. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled, double-blind trials. J Clin Psychopharmacol 1995; 15(3): 163–74
Covi L, Hess JM, Kreiter NA, et al. Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers. Am J Drug Alcohol Abuse 1995; 21(3): 327–44
Galloway GP, Newmeyer J, Knapp T, et al. Imipramine for the treatment of cocaine and methamphetamine dependence. J Addict Dis 1994; 13(4): 201–16
Nunes EV, McGrath PJ, Quitkin FM, et al. Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug Alcohol Depend 1995; 39(3): 185–95
Wolfsohn R, Angrist B. A pilot trial of levodopa/carbidopa in early cocaine abstinence. J Clin Psychopharmacol 1990; 10(6): 440–2
Chadwick MJ, Gregory DL, Wendung G. A double-blind amino acids, L-tryptophan and L-tyrosine, and placebo study with cocaine-dependent subjects in an inpatient chemical dependency treatment center. Am J Drug Abuse 1990; 16(3–4): 275–86
Kosten TR, Steinberg M, Diakogiannis IA. Crossover trial of mazindol for cocaine dependence. Am J Addict 1993; 2(2): 161–4
Preston KL, Sullivan JT, Berger P. Effects of cocaine alone and in combination with mazindol in human cocaine users. J Pharmacol Exp Ther 1993; 267: 296–307
Margolin A, Avants SK, Kosten TR. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am J Drug Alcohol Abuse 1995; 21(4): 469–81
Stine SM, Krystal JH, Kosten TR, et al. Mazindol treatment for cocaine dependence. Drug Alcohol Depend 1995; 39(3):245–52
Wiseman EJ, McMillan DE. Transdermal nicotine and drug craving. Am J Addict 1995; 4(3): 261–6
Muntaner C, Kumor KM, Nagoshi C, et al. Effects of nifedipine pretreatment on subjective and cardiovascular responses to intravenous cocaine in humans. Psychopharmacology 1991; 105(1): 37–51
Crosby RD, Pearson VL, Eller C, et al. Phenytoin in the treatment of cocaine abuse: a double-blind study. Clin Pharmacol Ther 1996; 59(4): 458–68
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. rev. Washington, DC: American Psychiatric Association, 1987
Kosten TR, Schumann B, Wright D, et al. A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients. J Clin Psychiatry 1987; 48(11): 442–4
Fischman MW, Foltin RW, Nestadt G, et al. Effects of desipramine maintenance on cocaine self-administration by humans. J Pharmacol Exp Ther 1990; 253(2): 760–70
Foltin RW, Fischman MW, Levin FR. Cardiovascular effects of cocaine in humans: laboratory studies. Drug Alcohol Depend 1995; 37(3): 193–210
Nunes EV, Quitkin FM, Brady R, et al. Imipramine treatment of methadone maintenance patients with affective disorder and illicit drug use. Am J Psychiatry 1991; 148(5): 667–9
Batki SL, Manfredi LB, Jacob P, et al. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. J Clin Psychopharmacol 1993; 13(4): 243–50
Batki SL, Washburn A, Manfredi LB, et al. Fluoxetine in primary and secondary cocaine dependence: outcome measured by quantitative benzoylecgonine concentration [abstract]. NIDA Res Monog; 141: 140, National Institute on Drug Abuse, NIH Public. No. 94-3749. Rockville (MD): US Department of Health and Human Services, 1994
Walsh SL, Preston KL, Sullivan JT, et al. Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol 1994; 14(6): 396–407
Hollister LE, Krajewski K, Rustin T, et al. Drugs for cocaine dependence: not easy [letter]. Arch Gen Psychiatry 1992; 49: 905
Montoya ID, Preston KL, Cone EJ, et al. Safety and efficacy of bupropion combined with bromocriptine for treatment of cocaine dependence. Am J Addict 1996; 5(1): 69–76
Halikas JA, Kuhn KL, Maddux TL. Reduction of cocaine use among methadone maintenance patients using concurrent carbamazepine. Ann Clin Psychiatry 1990; 2: 3–6
Berger P, Gawin F, Kosten TR. Treatment of cocaine abuse with mazindol [letter]. Lancet 1989 Feb; I: 283
Khantzian EJ, Gawin FH, Kleber HD, et al. Methylphenidate treatment of cocaine dependence — a preliminary report. J Subst Abuse Treat 1984; 1: 107–12
Kosten TR, Kleber HD, Morgan CH. Treatment of cocaine abuse with buprenorphine. Biol Psychiatry 1989; 26: 637–9
Kosten TR, Kleber HD, Morgan C. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci 1989; 44: 887–92
Wolfsohn R, Sanfilipo M, Angrist B. A placebo-controlled trial of L-dopa/carbidopa in early cocaine abstinence. Neuropsychopharmacology 1993; 9: 49–53
Higgins ST, Budney AJ, Bickel WK, et al. Disulfiram therapy in patients abusing cocaine and alcohol. Am J Psychiatry 1993; 150(4): 675–6
Carroll KM, Ziedonis D, O’Malley SS, et al. Pharmacological interventions for abusers of alcohol and cocaine: disulfiram versus naltrexone. Am J Addict 1993; 2: 77–9
Gawin FH, Khalsa-Denison EM, Jatlow P. Flupenthixol-induced aversion to crack cocaine. N Engl J Med 1996; 334(20): 1340–1
Gawin FH, Allen D, Humblestone B. Outpatient treatment of ‘crack’ cocaine smoking with flupenthixol decanoate. Arch Gen Psychiatry 1989; 46: 322–5
Khouzam HR, Mayo-Smith MF, Bernard DR, et al. Treatment of crack-cocaine-induced compulsive behavior with trazo-done. J Subst Abuse Treat 1995; 12(2): 85–8
Kosten TA, Kosten TR, Gawin FH. An open trial of sertraline for cocaine abuse. Am J Addict 1992; 1(4): 349–53
Goldwyn DH. Cocaine abuse treated with phenelzine. Int J Addict 1988; 23(9): 897–905
Margolin A, Avants SK, Falcioni J, et al. Preliminary investigation of selegiline for the treatment of cocaine dependence. Am J Addict 1996; 15(3): 275–6
Margolin A, Avants SK, Kosten TR. Pemoline for the treatment of cocaine dependence in methadone-maintained patients. J Psychoactive Drugs 1996; 28(3): 301–4
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nathan, K.I., Bresnick, W.H. & Batki, S.L. Cocaine Abuse and Dependence. Mol Diag Ther 10, 43–59 (1998). https://doi.org/10.2165/00023210-199810010-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-199810010-00004